Search tips
Search criteria 


Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
PLoS One. 2010; 5(12): e15740.
Published online 2010 December 23. doi:  10.1371/journal.pone.0015740
PMCID: PMC3009732

Polymorphisms in the Tlr4 and Tlr5 Gene Are Significantly Associated with Inflammatory Bowel Disease in German Shepherd Dogs

Holger K. Eltzschig, Editor


Inflammatory bowel disease (IBD) is considered to be the most common cause of vomiting and diarrhoea in dogs, and the German shepherd dog (GSD) is particularly susceptible. The exact aetiology of IBD is unknown, however associations have been identified between specific single-nucleotide polymorphisms (SNPs) in Toll-like receptors (TLRs) and human IBD. However, to date, no genetic studies have been undertaken in canine IBD. The aim of this study was to investigate whether polymorphisms in canine TLR 2, 4 and 5 genes are associated with IBD in GSDs. Mutational analysis of TLR2, TLR4 and TLR5 was performed in 10 unrelated GSDs with IBD. Four non-synonymous SNPs (T23C, G1039A, A1571T and G1807A) were identified in the TLR4 gene, and three non-synonymous SNPs (G22A, C100T and T1844C) were identified in the TLR5 gene. The non-synonymous SNPs identified in TLR4 and TLR5 were evaluated further in a case-control study using a SNaPSHOT multiplex reaction. Sequencing information from 55 unrelated GSDs with IBD were compared to a control group consisting of 61 unrelated GSDs. The G22A SNP in TLR5 was significantly associated with IBD in GSDs, whereas the remaining two SNPs were found to be significantly protective for IBD. Furthermore, the two SNPs in TLR4 (A1571T and G1807A) were in complete linkage disequilibrium, and were also significantly associated with IBD. The TLR5 risk haplotype (ACC) without the two associated TLR4 SNP alleles was significantly associated with IBD, however the presence of the two TLR4 SNP risk alleles without the TLR5 risk haplotype was not statistically associated with IBD. Our study suggests that the three TLR5 SNPs and two TLR4 SNPs; A1571T and G1807A could play a role in the pathogenesis of IBD in GSDs. Further studies are required to confirm the functional importance of these polymorphisms in the pathogenesis of this disease.


The healthy gut is able to regulate inflammatory responses to commensal bacteria and food antigens whilst maintaining the capacity to respond to pathogens [1], [2], [3]. This distinction relies on Toll-like receptors (TLRs) which are ideally situated on intestinal epithelia cells and recognise microbe associated molecular patterns (MAMPs) [4]. TLR2, TLR4 and TLR5 are particularly associated with recognition of lipoproteins, lipopolysaccharide and flagellin respectively [4]. A breakdown in this homeostatic response may lead to inflammatory bowel disease (IBD) in people as well as in dogs [1].

IBD is a chronic debilitating disease and occurs in both people and dogs. In dogs, it represents a group of disorders characterised by chronic gastro-intestinal signs, with histological evidence of inflammation in the lamina propria of the small intestine, large intestine or both [5]. In people, IBD consists of Crohn's disease (CD) and ulcerative colitis (UC)[6]. Inflammation associated with CD can occur in any area of the intestinal tract, although the terminal ileum is most commonly affected, whereas UC is confined to the colon [6]. CD typically involves granuloma formation and commonly involves the whole intestinal wall, while inflammation in UC is usually restricted to the superficial layers [6]. Canine IBD is a diagnosis of exclusion and in both dogs and people histopathology of intestinal sections are needed to make a definitive diagnosis [5], [6]. Immunosupressive therapy is the mainstay treatment for both human IBD and canine IBD patients [5], [6].

Although the exact aetiology of IBD is unknown it is considered a multifactorial disease with the mucosal immune system, microbiota, genetics and environment all playing a role[6], [7], [8], [9]. It is likely that human and canine IBD share similar aetiological factors as studies have already highlighted the importance of TLRs in IBD in both species. In human IBD, TLR 2,4 and 6 have been shown to be up-regulated in the intestine [10], [11], [12], whilst some studies have documented a down-regulation of TLR5[13], [14]. Similar to this, we have recently shown an upregulation of TLR 2,4 and 9 expression in the duodenum and colonic mucosa at the mRNA level in dogs with IBD of different breeds [15], [16]. Also, specific to German shepherd dogs (GSDs) with IBD, TLR4 was shown to be upregulated and TLR5 downregulated at the mRNA level [17].

In people a number of genetic polymorphisms have been reported to play a role in the pathogenesis of IBD, interestingly most of these genes are involved in the innate immune mechanism and primary defence against bacteria. Polymorphisms in the nucleotide oligomerisation domain 2 (NOD2) are considered the most important genetic susceptibility factor for CD, with approximately 20–40% of all patients carrying variants of this gene [18], [19]. However, polymorphisms in other innate immune receptors such as TLRs [20], [21], [22], the autophagy pathway (e.g. ATG16L1 and IGRM) [23], [24], cytokines (e.g. IL-10) [25] and their receptors (e.g IL23R) [26] and in human defensin (e.g. beta defensin 1) [27] genes have also been shown to be associated with IBD in people.

To date no genetic studies have been carried out in canine IBD. However, genetics are thought to play a fundamental role as certain breeds are susceptible to this disease. Retrospective analysis of the medical records at the Royal Veterinary College (RVC), UK, dating back over 10 years, revealed 555 dogs diagnosed with IBD. The GSD breed was the most common breed identified and represented 10% of the dogs diagnosed. We have previously demonstrated restriction of TLR5 allele frequencies in this breed by genetic analysis using microsatellite markers [28]. Furthermore, analysis of single nucleotide polymorphisms (SNPs) within the TLR5 gene demonstrated a significant difference in the GSD population compared to the general dog population [28]. This provides evidence that the underlying genetic make-up of this breed may be responsible for their increased susceptibility to IBD.

Comparisons of the canine and human TLR genetic sequences show a high degree of homology; this suggests that similar polymorphisms in the TLR genes seen in people with IBD may exist in dogs. Therefore, a candidate approach was used to test the hypothesis whether SNPs in genes for TLR2, TLR4 and TLR5 in GSDs are associated with IBD. We show that the TLR5 G22A, C100T, T1844C and the TLR4 SNP A1571T and G1807A SNPs are significantly associated with IBD in GSDs.


Mutational Analysis of TLR2/TLR4 and TLR5 genes

A mutational analysis of 10 GSDs with IBD was carried out to determine the number and nature of non-synonymous single nucleotide polymorphisms (SNPs) present in the TLR2, TLR4 and TLR5 gene. This analysis revealed that there were no non-synonymous SNPs in the coding region of the TLR2 gene. Four non-synonymous SNPs were identified in the TLR4 exons; T23C (ENSCAFT00000005653), G1039A (not reported on the Ensembl web server), A1571T (ENSCAFT00000005653) and G1807A (ENSCAFT00000005653) and three non-synonymous SNPs were identified in the TLR5 exon; G22A (ENSCAFT00000018059), C100T (ENSCAFT00000018059) and T1844C (ENSCAFT00000018059). All non-synonymous SNPs identified in the TLR4 and TLR5 gene resulted in a change in the class of amino acid coded (Table 1).

Table 1
Amino-acid change coded by non-synonymous single nucleotide polymorphisms in the canine TLR4 and TLR5 gene.

Case-control association study of TLR4 and TLR5 SNPs in German shepherd dogs

An association study was carried out to assess the significance of the non-synonymous SNPs identified by mutational analysis in GSDs with IBD. The case group consisted of 55 unrelated GSDs; 38 diagnosed with IBD at the Royal Veterinary College (RVC), UK and 17 diagnosed with IBD at the Small Animal Teaching Hospital, University of Liverpool (Table 2). The control population consisted of 61 GSDs, of which 47 dogs were diagnosed with non-inflammatory disease at the RVC, UK and 14 healthy GSDs (Table 2). The most common diagnosis for the group of GSDs diagnosed with non-inflammatory disease was neoplasia. Nineteen dogs fell into this latter category, 18 had neurological disease, three had musculoskeletal disease, two had gastrointestinal disease and there was one dog in the following aetiological categories; cardiovascular, dermatological and urogenital. Two dogs had other diseases that did not fit the above aetiological categories: one had suffered a road traffic accident, whilst the other had post-ovariohysterrectomy haemorrhage (Table 3).

Table 2
Signalment of cases and controls.
Table 3
Disease phenotype of controls dogs.

The minor allele frequencies for all the SNPs were >10% (Table 4). The presence of Hardy-Weinberg equilibrium was tested using the exact Hardy-Weinberg test [29] using the SNPSTATS programme [30]( Only three of the SNP alleles; TLR5 G22A, TLR4 T23C and TLR4 G1039A were in Hardy Weinberg equilibrium (P>0.05).

Table 4
Single nucleotide polymorphism allele association with inflammatory bowel disease in German shepherd dogs.

The significance of the SNP alleles was determined using the Haploview software package (version 4.1; All TLR5 SNP alleles and two of the TLR4 SNP alleles (A1571T and TLR4 G1807A) were found to be significantly associated with IBD in GSDs (Table 4).

To assess the importance of the identified associated SNP alleles in their genotype forms for association in IBD, five inheritance models (co-dominant, dominant, recessive, over-dominant and additive) were applied for statistical analysis to assess which one resulted in a best fit. The best inheritance model was assessed using the Akaike information criteria (AIC) and the Bayesian information criteria (BIC), with the model with the lowest values being the best fit [31], [32].

For the two TLR4 SNPs; A1571T and G1807A the recessive model was the best fit, where two copies of T and A respectively are necessary to increase the risk of developing IBD in GSDs (Table 5).

Table 5
TLR4 A1571T and TLR4 G1807A genotype association with inflammatory bowel disease in German shepherd dogs.

For the TLR5 G22A SNP, the best fit model was the additive model, where having each copy of A modifies the risk of developing IBD in an additive form. As a consequence, the homozygous AA GSD has a double risk of developing IBD compared to the GA genotype (p<0.0001, OR (95% CI) = 8.51 (2.71–26.70) (Table 6). However, the AIC and BIC for the dominant model was also low and very close to the additive model and, therefore, could also be a good fit model. For both the TLR5 SNPs C100T and T1844C, the T allele was significantly protective for IBD, and exerted a dominant effect (p<0.0001, OR = 0.19 [0.09–0.44, 95% CI]: p = 7e-04, OR = 0.25 [0.11–0.58, 95% CI], respectively; Table 6). Based on univariate analysis, age and sex were not significantly associated with SNP outcome (p>0.05).

Table 6
TLR5 G22A, TLR5 C100T and TLR5 T1844C genotype association with inflammatory bowel disease in German shepherd dogs.

The statistical correlation between different SNPs on the same gene was calculated to determine the inheritance pattern of alleles and the possible haplotype combinations. There was evidence of linkage disequilibrium (LD) between the SNPs in the TLR4 gene. TLR4 A1571T and TLR4 G1807A showed complete linkage, whereas TLR4 T23C and TLR4 G1039A showed no linkage which is not unexpected as they are present on different exons (Figure 1). There was also evidence of linkage between the three SNPs in the TLR5 gene with the TLR5 C100T and TLR5 T1844C showing the most linkage (Figure 2). There was also evidence of linkage amongst the other SNPs (Lod>3) (Figure 1 and and22).

Figure 1
Linkage disequilibrium of single nucleotide polymorphisms in canine TLR4.
Figure 2
Linkage disequilibrium of single nucleotide polymorphisms in canine TLR5.

LD analysis demonstrated significant linkage between SNPs on the same gene therefore haplotype analysis was carried out to determine their significance in IBD. The most significant haplotype combination was with the TLR5 G22A SNP, without the two protective TLR5 SNPs (C100T and T1844C) and with the two TLR4 SNPs (A1571T and G1807A) (p<0.0001). However, although the TLR5 risk haplotype (ACC) on its own without the two TLR4 SNPs was significantly associated with IBD (p = 0.029), a haplotype combination containing the two associated TLR4 SNPs without the associated TLR5 risk haplotype (ACC) was not statistically associated with IBD (p = 0.67). Of the six dogs that were homozygous recessive for the two associated TLR4 SNPs, five of these dogs had the risk haplotype for the three SNPs in their TLR5 gene (ACC).


The importance of TLRs in the pathogenesis of IBD in both people and dogs has been reported in the literature [10], [11], [12], [14], [15], [16]. Furthermore, SNPs in TLRs have been shown to be associated with IBD in people [20], [21], [22], [33], [34]. However, no genetic studies looking at SNPs in TLRs in canine IBD have been described. In this current study we identified three non-synonymous SNPs in the TLR5 gene (G22A, C100T and T1844C) and two non-synonymous SNPs in the TLR4 gene (A1571T and G1807A) to be significantly associated with IBD in GSDs.

Like all dog breeds the GSD has undergone selective breeding [28] and this may reflect why all the associated SNPs, except one (TLR5 G22A) were not in Hardy-Weinberg equilibrium. Additionally, for the TLR5 T1844C SNP the major allele, the T reported on the Ensembl webserver was the minor allele in the GSD population and was found to be protective for IBD. It is possible that selective breeding in the GSD population has resulted in loss of the protective effect of this major allele in the GSD population compared to the general dog population thus making them more susceptible to IBD. Similarly, for the TLR4 SNPs A1571T and G1807, the major allele reported on the ensemble webserver was the minor allele in the GSD population and was significantly associated with IBD. This may again reflect the selective breeding seen in this breed. Alternatively, it is possible that the data on the Ensembl webserver does not represent an accurate report of the major and minor alleles of the general canine population as the sequence data published is based only on a small number of breeds (Boxer and Standard Poodle).

In this study, all the SNPs associated with IBD result in a change in the class of amino acid coded. This may be significant as it could change the structural properties of the resulting TLR4 or TLR5 receptor, and therefore alter function. Interestingly, when the SNPs were protein modelled using the Simple modular architecture research tool (SMART) web server ([35], [36], the location of the majority of these SNPs was found to be in significant regions. Thus, both the TLR5 T1844C SNP and TLR4 G1807A SNP were found in the leucine-rich repeat (LRR) C-terminal domain, which is the region that folds into an arc or horse-shoe shape to form the ligand binding site in TLR–receptors [37]. In addition, the TLR4 SNP A1571T was also found in a LRR region which also contributes to the ligand binding site. The TLR5 G22A SNP was found to be in the signal peptide region when mapped using the SignalP 3.0 web server ( The signal peptide is important in the transport of proteins and a change in the amino acid may alter the cleavage site and, therefore, may result in a functional change to the TLR5 receptor [38].

Linkage disequilibrium (LD) in dogs is up to 100 times more extensive than in human beings [39]. It is therefore, possible that the associations we found, between SNPs in TLR4 and TLR5 and the development of IBD, are not the cause of the aberrant inflammation but are in LD with the causative gene. Functional analysis of these SNPs will help to confirm if TLR4 and TLR5 play a significant role in the pathogenesis of IBD in GSDs. However, the role of TLR5 in the pathogenesis of human IBD and murine colitis has been reported in the literature. TLR5 knockout mice develop spontaneous colitis and exhibit decreased intestinal expression of TLR5 [40]. Moreover, deletion of TLR4 rescued the colitis in these TLR5 knockout mice [40]. In addition, a dominant-negative TLR5 polymorphism termed TLR5-stop protected people of Jewish ethnicity against Crohn's disease (CD) [34]. It could be speculated that patients having the TLR5 stop polymorphism may also have a mutated TLR4 thus protecting them from IBD. Moreover, In CD patients, tolerance to commensal derived flagellin is lost and serum reactivity to flagellin can be demonstrated [41]. In addition, TLR5 signalling has been shown to play a role in defensin production [42]. One study showed that TLR5 uses gangliosides as co-receptors to bind flagellin leading to increased human beta defensin-2 expression in human colon adenocarcinoma (Caco)-2 cells [43]. This demonstrates that TLR5 activation may be needed for secretion of certain defensins. The reduced gene copy number of the beta-defensin cluster seen in CD patients may therefore be due to aberrant TLR5 activation [44], [45]. Clearly, evidence has accumulated that dysregulated TLR5 function may play a role in the pathogenesis of human IBD.

Similarly, several studies have looked at the role of TLR4 in human IBD. TLR4 expression is up-regulated in both Crohn's disease (CD) and ulcerative colitis (UC) [10], [11]. In paediatric IBD patients, higher levels of TLR4 mRNA and protein were found in the inflamed colonic mucosa [12]. This confers with our findings in canine IBD [15], [16], and specifically in GSDs [17]. Epidemiological studies have also shown an association between TLR4 polymorphism and susceptibility to IBD in people. A Belgian cohort found that the allele frequency of the TLR4 A299G polymorphism was significantly higher in CD and UC patients [21]. Furthermore, the A299G SNP has been shown to be associated with reduced responsiveness following lipopolysaccharide stimulation [46]. Another TLR4 polymorphism, T399IL, was exclusively associated with UC but not CD [22].

Of the six dogs in the case population that harboured the TLR4 SNPs in a recessive genotype, five of them also had the risk haplotype for all three TLR5 SNPs (ACC). This suggests that the TLR4 SNPs may need to be present with the TLR5 SNPs in order for them to have a significant effect. It is known that TLR4 and TLR5 are able to form heterodimeric complexes and this enhances the diversity of the response to flagellin [47]. Therefore, the functional consequence of the TLR4 mutations may be acting via TLR5 signalling and so having both TLR4 and TLR5 SNPs may affect intracellular signalling after ligation of flagellin more than just the TLR5 SNPs on their own.

Our results from the mutational analysis showed that no TLR2 non-synonymous SNPs could be identified in the coding region of the gene. This finding is also mirrored in the literature as there are no published or identified non-synonymous SNPs in the canine TLR2 exon gene. Moreover, we could not detect upregulation of TLR2 mRNA in intestinal biopsies in GSDs with IBD [17]. However, the role of TLR2 in canine IBD cannot be completely eliminated as some studies, including dogs of many different breeds, have shown an up-regulation at the mRNA level in dogs with chronic enteropathies [15], [16]. This could be due to SNPs present in the promoter region of the TLR2 gene which was not investigated in this study or could be a consequence of the disease process rather than the cause.

One potential limitation of this study may be the selection and inclusion of controls having non-inflammatory disease. Although retrospective phenotyping was carried out to ensure that none of these dogs had inflammatory, infectious or immune-mediated disease, this type of inquiry can be imprecise and therefore may have led to some GSDs inappropriately being included in the control group as they may have later developed these diseases. However, to control for this, GSDs older than 4 years were recruited as controls and 75% of dogs in our control group were 5 years or older. This resulted in a significant difference in the age groups between the case and control population. However, we did have 14 completely healthy dogs in our control group, who were all over the age of 4 years and none of these dogs had the TLR5 risk haplotype (ACC) nor the two TLR4 recessive SNPs, further supporting the role of these SNPs in canine IBD in GSDs. Another potential limitation of this study was that the degree of relatedness of the dogs could not be assessed as most of these dogs were not registered with the UK Kennel Club. This may have skewed the results; however, none of the dogs belonged to the same litter. Previous studies have shown that the GSD breed is one of the most diverse dog breeds as it has retained a large range of Dog Leucocyte Antigen (DLA) haplotypes and therefore represents a breed that has been less selectively in-bred than other dog breeds [48]. Moreover, we have shown in a previous study that the same non-synonymous SNPs in the TLR5 gene are not associated with anal furunculosis in GSDs, which is another immune-mediated disease commonly seen in this breed. [28]

In conclusion, we have identified an association between three non-synonymous SNPs in the TLR5 gene (G22A, C100T and T1844C) and two non-synonymous SNPs in the TLR4 gene (A1571T and 1807A) with IBD in the GSD population. Studying the functional significance of these SNPs will not only help to confirm their importance in IBD but will also help to increase our understanding of the pathogenesis of these diseases in dogs and in man. In addition, as the pathogenesis of IBD is multifactorial, studying the nutrition and maintenance conditions of dogs with and without the mutations may help determine key triggering factors in the intestinal microbiota that are responsible for bringing about these changes and may therefore allow the development of preventative strategies not only in the dog but also in people.

Materials and Methods

Ethics Statement

Ethics approval for the recruitment of healthy German shepherd dogs was sought and approved from the Ethics Committee at the Royal Veterinary College (URN 2010 1035).

Sample population

The case population included 55 GSDs; 38 were diagnosed with inflammatory bowel disease at the Royal Veterinary College, UK and 17 at the Small Animal Teaching Hospital, University of Liverpool, UK. For all cases, the diagnostic work-up was reviewed. All cases had complete medical records consisting of a detailed history at first examination and at subsequent re-examinations, haematology and biochemistry results, detailed abdominal ultrasonography report and detailed histopathology reports. All known causes of gastrointestinal inflammation including enteropathogenic bacteria were ruled out by routine haematology and biochemistry, faecal analysis, ultrasound and measurement of serum trypsin-like immunoreactivity concentration. Definitive diagnosis of IBD was based on histological evidence of an inflammatory infiltrate within the lamina propria of endoscopically obtained intestinal biopsies.

The control population consisted of 47 unrelated GSDs from the UK. These were retrospectively phenotyped, either by owner or veterinary surgeon telephone contact, to ensure they had no inflammatory, immune-mediated or infectious disease. Fourteen additional GSDs were also included in the control group; six of these were enrolled from the blood donor programme at the RVC and eight were recruited exclusively for the study. Ethics approval was granted from the Royal Veterinary College, UK for the recruitment of these eight dogs.

Blood stored in Ethylenediaminetetraacetic acid (EDTA) was collected from the DNA archive for those cases that were seen at the RVC. For the cases from Liverpool, paraffin sections of intestinal tissue were available. Residual blood from the blood donor dogs and from the eight dogs following collection of blood for folate and cobalamin concentrations as a screening test for intestinal health were collected into EDTA tubes.

Mutational Analysis of TLR2/TLR4 and TLR5 genes

A mutational analysis of the TLR2, TLR4 and TLR5 exons was carried out, in 10 GSDs diagnosed with IBD, to determine the presence and frequency of non-synonymous SNPs in the coding regions of the genes, so that these could be investigated further in a case-control association study to determine their significance in IBD in the GSD population.

Ten cases of GSDs with IBD were selected from the 38 diagnosed at the RVC and genomic DNA was extracted from blood stored in EDTA using the Qiagen DNeasy blood and tissue kit (Qiagen, Crawley, UK) according to the manufacturer's protocol.

Full-length canine TLR2, TLR4 and TLR5 forward and reverse primers were designed using the Integrated DNA technology oligoanalyzer 3.1 programme ( (Table 7) based on the full sequences for canine TLR2, TLR4 and TLR5.

Table 7
Primers used in mutational analysis of TLR4 and TLR5.

Easy A 2X master mix (Stratagene, California, USA) was used for polymerase chain reaction (PCR) with reactions heated to 95°C for 10 min, followed by 30 cycles of 95°C for 1 min, 55°C for 1 min and 72°C for 3 mins then a further 72°C for 7 mins.

Full-length PCR products were electrophoresed with 6X orange loading dye (Fermentas, UK) on a 1% agarose/safeview nucleic stain (NBS Biologicals, Huntington, UK) gel in 1X Tris-Borate EDTA (TBE) buffer using the power pack FB 300 (Fischer Scientific, UK). The gels were visualised under UV light (Ultraviolet Transilluminator, UVP, California,USA), and the bands cut out and placed into separate eppendorf tubes. DNA was extracted using the Qiagen mini-elute extraction kit (Qiagen, Crawley, UK), according to manufacturer's instructions.

Gel purified PCR products were sent to Geneservice, Cambridge, UK for sequencing using sequencing primers specifically designed to cover the entire sequence of the exons (Table 8).

Table 8
Sequencing primers used in mutational analysis of TLR4 and TLR5.

Sequence data was compared to the canine genome ( and CLC DNA Workbench version 5.1 (CLC Bio) used to identify non-synonymous SNPs present in the genes.

Determining the allele frequency of TLR4 and TLR5 SNPs in healthy GSDs and those affected with IBD using SNaPSHOT multiplex reaction

Non-synonymous SNPs identified by mutational analysis in the TLR2, TLR4 and TLR5 exon genes were analysed further in a case population consisting of 55 GSDs with IBD and a control population consisting of 61 GSDs; 47 with non-inflammatory disease and 14 healthy. Genotyping of all SNPs was carried out by primer extension using the ABI PRISM SNaPSHOT Multiplex Kit (Applied Biosystems).

Genomic DNA was extracted from blood stored in EDTA from the remainder of the 28 IBD cases seen at the RVC and from the 61 control GSDs using the Qiagen DNeasy blood and tissue kit (Qiagen, Crawley, UK) according to the manufacturer's protocol. This kit along with the manufacturer's recommendations was also used to extract genomic DNA from the paraffin sections from the 17 cases diagnosed with IBD at the University of Liverpool.

PCR was carried out on all samples using amplification primers to yield a fragment size containing the SNPs that was less than 1200 base pairs (Table 9). Immolase DNA polymerase (Bioline, London, UK) was used for PCR with reactions heated to 95°C for 10 min, followed by 35 cycles if 95°C for 1 min, 52°C for 1 min and 72°C for 2 mins, then a further 72°C for 7 mins.

Table 9
Fragment amplification primers used in SNaPSHOT reaction of TLR4 and TLR5.

Five micro-litres of PCR product from each sample was added to 2 µL of ExoSAP-IT (United States Biochemical (USB), USA) and mixed thoroughly and incubated for an hour at 37°C and then at 75°C for 15 minutes.

Sequencing primers of different lengths for the SNaPSHOT reaction were designed to stop just one base before the SNP (Table 10). All SNaPSHOT primers were diluted to give a concentration of 0.2 µL as a working solution. For multiplexing 0.2 µM concentration of each primer was used.

Table 10
Sequencing primers used in SNaPSHOT reaction of TLR4 and TLR5.

The SNaPSHOT multiplex reaction mix (ABI prisms, Applied Biosystems) was thawed on ice. For each reaction the following was added to a 96-well plate: 4 µL undiluted DNA ExoSAP-IT cleaned template, 1 µL SNaPSHOT SNP primer mix, 2 µL SNaPSHOT reagent mix, 2 µL sequencing buffer (ABI prisms, Applied Biosystems) and 1 µL MWB.

The plate was incubated at 96°C for 10 seconds, 50°C for 5 seconds and at 60°C for 30 seconds. This was repeated for 25 cycles.

Once the sequencing reaction was complete the samples were removed from the thermal cycler and 1 µL of shrimp alkaline phosphatase (SAP) (USB, USA) was added to each well. The plate was then incubated at 37°C for one hour and the enzyme deactivated by incubating at 75°C for 15 minutes.

A master mix was made up per reaction well of 9.0 µL Hi-Di Formamide (ABI prisms, Applied Biosystems) and 0.5 µL Gene-Scan 120 Liz size standard (ABI prisms, Applied Biosystems). Half a micro-litre of SAP cleaned SNaPSHOT product was aliquotted into a red fisher plate (Fisher Scientific, UK). Nine and a half micro-litres of master mix was added to each well. The plate was covered with a 96 well grey septa and spun briefly in a centrifuge. The plate was then denatured at 95°C for 3 minutes and snap cooled on ice for 5 minutes and placed in ABI Prism 3100 genetic analyzer for electrophoresis.

Electrophoresis results were analysed using Genemapper (version 3.2.1) software (Applied Biosytems). Allele frequency, association and linkage disequilibrium data for all the SNPs were statistically assessed using Haploview software package (version 4.1; The calculation of Hardy-Weinberg equilibrium and further genotype and haplotype associations for all the SNPs were carried out using SNPSTATS programme ( Statistical significance was set at P<0·05.


Competing Interests: AK's PhD is funded by Pfizer and the Biotechnology and Biological Sciences Research Council - BBSRC. In addition, a grant from PetSavers was used to also fund this research. AG's senior lectureship is funded by Royal Canin. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.

Funding: This research was funded by Biotechnology and Biological Sciences Research Council (BBSRC), Pfizer and Petsavers. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.


1. Abreu MT, Fukata M, Arditi M. TLR signaling in the gut in health and disease. J Immunol. 2005;174:4453–4460. [PubMed]
2. Magalhaes JG, Tattoli I, Girardin SE. The intestinal epithelial barrier: how to distinguish between the microbial flora and pathogens. Semin Immunol. 2007;19:106–115. [PubMed]
3. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell. 2004;118:229–241. [PubMed]
4. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124:783–801. [PubMed]
5. Guilford WG. Strombecks Small Animal Gastroenterology; 1996. Idiopathic Inflammatory Bowel disease. pp. 451–486.
6. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427–434. [PubMed]
7. Blumberg RS, Saubermann LJ, Strober W. Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. Curr Opin Immunol. 1999;11:648–656. [PubMed]
8. Fritz JH, Le Bourhis L, Magalhaes JG, Philpott DJ. Innate immune recognition at the epithelial barrier drives adaptive immunity: APCs take the back seat. Trends Immunol. 2008;29:41–49. [PubMed]
9. Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev. 2002;15:79–94. [PMC free article] [PubMed]
10. Frolova L, Drastich P, Rossmann P, Klimesova K, Tlaskalova-Hogenova H. Expression of Toll-like Receptor 2 (TLR2), TLR4, and CD14 in Biopsy Samples of Patients With Inflammatory Bowel Diseases: Upregulated Expression of TLR2 in Terminal Ileum of Patients With Ulcerative Colitis. J Histochem Cytochem 2007 [PubMed]
11. Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun. 2000;68:7010–7017. [PMC free article] [PubMed]
12. Szebeni B, Veres G, Dezsofi A, Rusai K, Vannay A, et al. Increased expression of Toll-like receptor (TLR) 2 and TLR4 in the colonic mucosa of children with inflammatory bowel disease. Clin Exp Immunol. 2008;151:34–41. [PubMed]
13. Ortega-Cava CF, Ishihara S, Rumi MA, Aziz MM, Kazumori H, et al. Epithelial toll-like receptor 5 is constitutively localized in the mouse cecum and exhibits distinctive down-regulation during experimental colitis. Clin Vaccine Immunol. 2006;13:132–138. [PMC free article] [PubMed]
14. Stanislawowski M, Wierzbicki PM, Golab A, Adrych K, Kartanowicz D, et al. Decreased Toll-like receptor-5 (TLR-5) expression in the mucosa of ulcerative colitis patients. J Physiol Pharmacol. 2009;60(Suppl 4):71–75. [PubMed]
15. McMahon LA, House AK, Catchpole B, Elson-Riggins J, Riddle A, et al. Expression of Toll-like receptor 2 in duodenal biopsies from dogs with inflammatory bowel disease is associated with severity of disease. Vet Immunol Immunopathol. 2010;135:158–163. [PubMed]
16. Burgener IA, Konig A, Allenspach K, Sauter SN, Boisclair J, et al. Upregulation of toll-like receptors in chronic enteropathies in dogs. J Vet Intern Med. 2008;22:553–560. [PubMed]
17. Allenspach K. Evaluation of mucosal bacteria and histopathology, clinical disease activity and expression of Toll-like receptors in German shepherd dogs with chronic enteropathies Vet Microbiol. 2010. [PubMed]
18. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001;411:603–606. [PubMed]
19. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001;411:599–603. [PubMed]
20. Browning BL, Huebner C, Petermann I, Gearry RB, Barclay ML, et al. Has toll-like receptor 4 been prematurely dismissed as an inflammatory bowel disease gene? Association study combined with meta-analysis shows strong evidence for association. Am J Gastroenterol. 2007;102:2504–2512. [PubMed]
21. Franchimont D, Vermeire S, El Housni H, Pierik M, Van Steen K, et al. Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut. 2004;53:987–992. [PMC free article] [PubMed]
22. Torok HP, Glas J, Tonenchi L, Mussack T, Folwaczny C. Polymorphisms of the lipopolysaccharide-signaling complex in inflammatory bowel disease: association of a mutation in the Toll-like receptor 4 gene with ulcerative colitis. Clin Immunol. 2004;112:85–91. [PubMed]
23. Hampe J, Franke A, Rosenstiel P, Till A, Teuber M, et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet. 2007;39:207–211. [PubMed]
24. Parkes M, Barrett JC, Prescott NJ, Tremelling M, Anderson CA, et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat Genet. 2007;39:830–832. [PMC free article] [PubMed]
25. Franke A, Balschun T, Karlsen TH, Sventoraityte J, Nikolaus S, et al. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet. 2008;40:1319–1323. [PubMed]
26. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006;314:1461–1463. [PubMed]
27. Kocsis AK, Lakatos PL, Somogyvari F, Fuszek P, Papp J, et al. Association of beta-defensin 1 single nucleotide polymorphisms with Crohn's disease. Scand J Gastroenterol. 2008;43:299–307. [PubMed]
28. House AK, Binns MM, Gregory SP, Catchpole B. Analysis of NOD1, NOD2, TLR1, TLR2, TLR4, TLR5, TLR6 and TLR9 genes in anal furunculosis of German shepherd dogs. Tissue Antigens. 2009;73:250–254. [PubMed]
29. Guo SW, Thompson EA. Performing the exact test of Hardy-Weinberg proportion for multiple alleles. Biometrics. 1992;48:361–372. [PubMed]
30. Sole X, Guino E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinformatics. 2006;22:1928–1929. [PubMed]
31. Schwarz G. Estimating the dimension of a model. Ann Stat. 1978;6:461–464.
32. Akaike H. A new look at the statistical model identification. IEEE Transactions on Automatic Control. 1974;19:716–723.
33. Pierik M, Joossens S, Van Steen K, Van Schuerbeek N, Vlietinck R, et al. Toll-like receptor-1, -2, and -6 polymorphisms influence disease extension in inflammatory bowel diseases. Inflamm Bowel Dis. 2006;12:1–8. [PubMed]
34. Gewirtz AT, Vijay-Kumar M, Brant SR, Duerr RH, Nicolae DL, et al. Dominant-negative TLR5 polymorphism reduces adaptive immune response to flagellin and negatively associates with Crohn's disease. Am J Physiol Gastrointest Liver Physiol. 2006;290:G1157–1163. [PubMed]
35. Schultz J, Milpetz F, Bork P, Ponting CP. SMART, a simple modular architecture research tool: identification of signaling domains. Proc Natl Acad Sci U S A. 1998;95:5857–5864. [PubMed]
36. Letunic I, Doerks T, Bork P. SMART 6: recent updates and new developments. Nucleic Acids Res. 2009;37:D229–232. [PMC free article] [PubMed]
37. McEwan PA, Scott PG, Bishop PN, Bella J. Structural correlations in the family of small leucine-rich repeat proteins and proteoglycans. J Struct Biol. 2006;155:294–305. [PubMed]
38. Austen BM, Ridd DH. The signal peptide and its role in membrane penetration. Biochem Soc Symp. 1981:235–258. [PubMed]
39. Sutter NB, Eberle MA, Parker HG, Pullar BJ, Kirkness EF, et al. Extensive and breed-specific linkage disequilibrium in Canis familiaris. Genome Res. 2004;14:2388–2396. [PubMed]
40. Vijay-Kumar M, Sanders CJ, Taylor RT, Kumar A, Aitken JD, et al. Deletion of TLR5 results in spontaneous colitis in mice. J Clin Invest. 2007;117:3909–3921. [PMC free article] [PubMed]
41. Lodes MJ, Cong Y, Elson CO, Mohamath R, Landers CJ, et al. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest. 2004;113:1296–1306. [PMC free article] [PubMed]
42. Palazzo M, Balsari A, Rossini A, Selleri S, Calcaterra C, et al. Activation of enteroendocrine cells via TLRs induces hormone, chemokine, and defensin secretion. J Immunol. 2007;178:4296–4303. [PubMed]
43. Ogushi K, Wada A, Niidome T, Okuda T, Llanes R, et al. Gangliosides act as co-receptors for Salmonella enteritidis FliC and promote FliC induction of human beta-defensin-2 expression in Caco-2 cells. J Biol Chem. 2004;279:12213–12219. [PubMed]
44. Hollox EJ, Armour JA, Barber JC. Extensive normal copy number variation of a beta-defensin antimicrobial-gene cluster. Am J Hum Genet. 2003;73:591–600. [PubMed]
45. Groth M, Szafranski K, Taudien S, Huse K, Mueller O, et al. High-resolution mapping of the 8p23.1 beta-defensin cluster reveals strictly concordant copy number variation of all genes. Hum Mutat. 2008;29:1247–1254. [PubMed]
46. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet. 2000;25:187–191. [PubMed]
47. Honko AN, Mizel SB. Effects of flagellin on innate and adaptive immunity. Immunol Res. 2005;33:83–101. [PubMed]
48. Kennedy LJ, Carter SD, Barnes A, Bell S, Bennett D, et al. Interbreed variation of DLA-DRB1, DQA1 alleles and haplotypes in the dog. Vet Immunol Immunopathol. 1999;69:101–111. [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science